JP2024544936A - 組成物 - Google Patents

組成物 Download PDF

Info

Publication number
JP2024544936A
JP2024544936A JP2024527607A JP2024527607A JP2024544936A JP 2024544936 A JP2024544936 A JP 2024544936A JP 2024527607 A JP2024527607 A JP 2024527607A JP 2024527607 A JP2024527607 A JP 2024527607A JP 2024544936 A JP2024544936 A JP 2024544936A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544936A5 (enExample
Inventor
ソーミナーデン，コビレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RQ Biotechnology Ltd
Original Assignee
RQ Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2116386.0A external-priority patent/GB202116386D0/en
Priority claimed from GBGB2116387.8A external-priority patent/GB202116387D0/en
Priority claimed from GBGB2116388.6A external-priority patent/GB202116388D0/en
Application filed by RQ Biotechnology Ltd filed Critical RQ Biotechnology Ltd
Publication of JP2024544936A publication Critical patent/JP2024544936A/ja
Publication of JP2024544936A5 publication Critical patent/JP2024544936A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024527607A 2021-11-12 2022-11-11 組成物 Pending JP2024544936A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2116388.6 2021-11-12
GBGB2116386.0A GB202116386D0 (en) 2021-11-12 2021-11-12 Compositions
GB2116386.0 2021-11-12
GBGB2116387.8A GB202116387D0 (en) 2021-11-12 2021-11-12 Compositions
GB2116387.8 2021-11-12
GBGB2116388.6A GB202116388D0 (en) 2021-11-12 2021-11-12 Compositions
PCT/EP2022/081676 WO2023084055A1 (en) 2021-11-12 2022-11-11 Compositions

Publications (2)

Publication Number Publication Date
JP2024544936A true JP2024544936A (ja) 2024-12-05
JP2024544936A5 JP2024544936A5 (enExample) 2025-11-19

Family

ID=84389199

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527607A Pending JP2024544936A (ja) 2021-11-12 2022-11-11 組成物

Country Status (4)

Country Link
US (1) US20250011398A1 (enExample)
EP (1) EP4430070A1 (enExample)
JP (1) JP2024544936A (enExample)
WO (1) WO2023084055A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
CR20240528A (es) 2022-04-29 2025-04-04 Astrazeneca Uk Ltd Anticuerpos contra el sars-cov-2 y métodos para utilizarlos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517234A (ja) * 2020-03-09 2023-04-24 アブセレラ バイオロジクス インコーポレイテッド 抗コロナウイルス抗体および使用の方法
CR20220552A (es) * 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
US20240043507A1 (en) * 2021-02-04 2024-02-08 Rq Biotechnology Limited Antibodies

Also Published As

Publication number Publication date
EP4430070A1 (en) 2024-09-18
WO2023084055A1 (en) 2023-05-19
US20250011398A1 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
US20250011398A1 (en) Compostions
JP2023062036A (ja) ジカウイルスエピトープに特異的に結合する新規抗体及びその使用
US20240254207A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
JP7664212B2 (ja) 抗ｃｈｉｋｖ抗体およびその使用
US10981977B2 (en) Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis
JP7463366B2 (ja) 新規の抗ジカウイルス抗体及びその使用
JP2024509054A (ja) 抗体
JP7689955B2 (ja) 抗水痘帯状疱疹ウイルス抗体
US20260139035A1 (en) Human antibody against coronavirus variants or antigen-binding fragment thereof
CN111153990B (zh) 针对Echo30的单克隆抗体、制备方法及其应用
US20260092103A1 (en) Monoclonal antibodies to arabinomannan (am), groel2, and lprg and methods of use
CN118871461A (zh) 组合物
JP2026508140A (ja) 帯状疱疹の治療
WO2026030604A1 (en) Human anti-sars-cov-2 spike (s) antibodies
WO2025083216A1 (en) Antibodies specific for the spike protein of sars cov-2 coronavirus
EA042611B1 (ru) Антитела против chikv и пути их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251111